Formulation Development
Rigel Pharmaceuticals & Forma Therapeutics Announce Licensing Agreement for Novel Mutant IDH1 Inhibitor
Rigel Pharmaceuticals, Inc. and Forma Therapeutics, Inc. recently announced they have entered into an exclusive, worldwide license agreement to develop, manufacture, and commercialize….
US Patent Issued to HCW Biologics for Foundational Platform Technology
HCW Biologics Inc. was granted US Patent No. 11,401,324, which contains claims for immunotherapeutic compounds comprised of a single-chain chimeric polypeptide with two target-binding domains…
Ocuphire Extends US Patent Protection for Late-Stage Drug Candidate for Reversal of Mydriasis by 5 More Years Into 2039
Ocuphire Pharma, Inc. recently announced the issuance of US Patent No. 11,400,077. The patent provides added intellectual property protection for the company’s late-stage product candidate,…
Athira Pharma Presents Data From ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients
Athira Pharma, Inc. recently announced Hans Moebius, MD, PhD, Athira’s Chief Medical Officer, is leading an oral presentation titled ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease…
Cornerstone Pharmaceuticals Announces Successful Completion of Phase 1b Clinical Trial
Cornerstone Pharmaceuticals, Inc. recently announced the successful completion of a Phase 1b clinical trial of CPI-613 (devimistat) in combination with gemcitabine and cisplatin for the treatment…
PolyPid Announces Exclusive Licensing Agreement With Advanz Pharma
PolyPid Ltd. recently announced it has entered into an exclusive licensing agreement with ADVANZ PHARMA Corp. for the commercialization of its lead drug candidate, D-PLEX100 for the prevention of….
New Lipid Facility at Evonik’s Site in Hanau to Produce Clinical & Launch Quantities of Lipids for Innovative Medicines
Evonik is building a new cGMP facility to manufacture lipids for clinical development and launch of innovative medicines. The new cGMP lipid launch facility is located in….
Context Therapeutics & The Menarini Group Announce Clinical Trial Collaboration & Supply Agreement
Context Therapeutics Inc. and The Menarini Group recently announced a clinical trial collaboration and supply agreement for Menarini’s oral selective estrogen receptor degrader (SERD), elacestrant.…
Curia Appoints Niall Condon to Lead Manufacturing
Curia recently announced the appointment of Niall Condon as President of its Manufacturing Division, with immediate effect. Condon will drive growth and be responsible for…
Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq:…
Verrica Pharmaceuticals Announces Start of Phase 3 Trial for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals Inc. recently announced Torii Pharmaceutical Co., Ltd. dosed the first patient in its Phase 3 trial of VP-102 (referred to as TO-208 in…
Avalo Therapeutics Transfers Anti-IL-18 Antibody to Apollo Therapeutics
Avalo Therapeutics, Inc. and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive license agreement granting rights to Apollo to research, develop, manufacture and commercialize….
CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients With Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. recently announced the completion of enrollment for RESPONSE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary….
Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates
Vaxxinity, Inc. recently presented new preclinical data on vaccine candidates targeting aberrant forms of the Tau protein for Alzheimer’s disease (AD) during a poster session at the….
Akari Therapeutics Narrows Pipeline Focus
Akari Therapeutics, Plc recently announced it is prioritizing two pipeline programs. Cash and resources will be reallocated to the Phase 3 clinical trial of nomacopan…
Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 in Advanced Solid Tumors
Agenus Inc. recently announced the first patient has been dosed in the Phase 1 study of AGEN1571 in advanced solid tumors. The dose-escalation and expansion…
SciSparc Signs Clinical Trial Agreement With Yale University to Conduct Phase 2b Trial in Tourette Syndrome
SciSparc Ltd. recently announced the addition of another site of excellence, the Yale Child Study Center at Yale University, to its Phase 2b clinical trial…
Nanoform & Pharmanovia to Breathe New Life Into Iconic Medicines
Nanoform Finland Plc. recently announced it has partnered with Pharmanovia, a fast-growing specialty pharma business with a portfolio of over 20 branded drugs in 140 markets…..
TFF Pharmaceuticals Expands R&D Operations With New Austin Facility
TFF Pharmaceuticals, Inc. recently announced a significant expansion of its R&D operations through the lease of a new research and development facility located in Austin,…
US Alliance Pharma Acquires UK-Based LGC’s Drug Development Solutions Business
Alliance Pharma recently closed on the purchase of Drug Development Solutions (DDS) from LGC. Ampersand Capital Partners, a global healthcare private equity firm, and KKR & Co. Inc., a leading global investment….
